We asked AI no. 5: “What Alternative Markets?”
Could the TITAN Platform’s versatility confront insulin injustice by increasing availability and lowering cost?
As we finalise the design for TITAN’s cutting-edge ethanol production, our focus extends beyond conventional energy solutions towards pioneering advancements in healthcare. With the potential to revolutionise the production of insulin, TITAN embodies a vision of innovation that transcends traditional boundaries.
The decision to explore insulin production stems from the alarming rise of diabetes, particularly in the United States and Europe. Diabetes has become an epidemic, with its prevalence mirroring the exponential growth of obesity rates. In the U.S. alone, nearly 10 per cent of the population suffers from diabetes, while another 12 per cent are at high risk due to factors like obesity.
This epidemic imposes significant financial and human costs, with healthcare expenditures related to diabetes reaching billions annually. Moreover, poorly managed diabetes leads to severe complications such as kidney disease, heart disease, and blindness, further exacerbating the crisis.